While a number of aptamers have completed various stages of preclinical development, only one aptamer (targeting vascular endothelial growth factor) completed phase III clinical trials and is now marketed for the treatment of age-related macular degeneration [10,161]. Here, VEGFA is linked to age-related macular degeneration.